The women’s health market is predicted to be among the fastest growing investment areas within the healthcare and life sciences industry. Life sciences companies and healthcare providers, as well as the governmental bodies that regulate them, are abandoning a “one-size-fits-all” approach to treatment in favor of approaches more tailored to specific groups, including women. King & Spalding’s Women’s Health team has decades of experience advising companies in this space on issues that arise throughout the lifecycle of medical products – including intellectual property issues, corporate and M&A issues, FDA-related issues, issues related to product coverage and reimbursement, healthcare provider issues, and product liability issues. Clients include drug and device manufacturers, health care providers, private equity firms, and others.
Back to Focus on Women's Health
March 30, 2023
Product Testing, Questionable Science, and the Smallest, Big Developments in Consumer Product Litigation
March 14, 2022
Health Headlines– March 14, 2022
February 7, 2022
A Pandemic Silver Lining: FDA’s New Guidance on Using Digital Health Technologies for Clinical Investigations
August 23, 2023
Medical device partner Jeff Shapiro joins the firm’s Government Matters practice group in Washington, D.C.
August 23, 2023
Leading Medical Device Lawyer Jeff Shapiro Joins King & Spalding in Washington, D.C.
August 11, 2023
K&S obtains a favorable outcome before the Eighth Circuit which affirmed a summary judgement to Coloplast
King & Spalding Advised the Founder, CEO and Majority Owner of Vogue International in Its $3.3 Billion Sale to Johnson & Johnson Consumer Inc.
Eva Temkin to Speak at Fierce Biotech Summit